felodipine has been researched along with Celiac Disease in 2 studies
Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.
felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.
Celiac Disease: A malabsorption syndrome that is precipitated by the ingestion of foods containing GLUTEN, such as wheat, rye, and barley. It is characterized by INFLAMMATION of the SMALL INTESTINE, loss of MICROVILLI structure, failed INTESTINAL ABSORPTION, and MALNUTRITION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A physiologically-based pharmacokinetic (PBPK) population for different severities of CeD was developed." | 5.91 | Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. ( Bloomer, J; Mudunuru, J; Nimavardi, A; Salem, F; Taskar, KS; Tompson, D; Turner, DB, 2023) |
| "A phase I, open-label, single-dose, pharmacokinetic study." | 2.94 | Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. ( Asher, L; Bailey, DG; Chretien, ML; Dresser, GK; Driman, D; Gregor, J; Parfitt, J, 2020) |
| " A physiologically-based pharmacokinetic (PBPK) population for different severities of CeD was developed." | 1.91 | Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug. ( Bloomer, J; Mudunuru, J; Nimavardi, A; Salem, F; Taskar, KS; Tompson, D; Turner, DB, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salem, F | 1 |
| Nimavardi, A | 1 |
| Mudunuru, J | 1 |
| Tompson, D | 1 |
| Bloomer, J | 1 |
| Turner, DB | 1 |
| Taskar, KS | 1 |
| Chretien, ML | 1 |
| Bailey, DG | 1 |
| Asher, L | 1 |
| Parfitt, J | 1 |
| Driman, D | 1 |
| Gregor, J | 1 |
| Dresser, GK | 1 |
1 trial available for felodipine and Celiac Disease
| Article | Year |
|---|---|
Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study.
Topics: Adult; Aged; Celiac Disease; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Dose-Respo | 2020 |
1 other study available for felodipine and Celiac Disease
| Article | Year |
|---|---|
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.
Topics: Celiac Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Felodi | 2023 |